Cystic fibrosis year in review 2019: Section 1 CFTR modulators

Pediatr Pulmonol. 2020 Dec;55(12):3236-3242. doi: 10.1002/ppul.25039. Epub 2020 Sep 1.

Abstract

During the year 2019, research and case reports/series in the field of cystic fibrosis (CF) were in abundance. To adequately address the large body of CF research published during 2019, the CF year in review will be divided into three sections. This report is the first section, focusing specifically on new research related to cystic fibrosis transmembrane conductance regulator modulator therapy. Additional sections will concentrate on pulmonary and infections research and the multisystem effects of CF. It is an exciting time to be providing care for patients and their families with CF with all the exciting new discoveries that will be shared in these reviews.

Keywords: clinical trials; cystic fibrosis; evidence-based medicine and outcomes.

Publication types

  • Review

MeSH terms

  • Cystic Fibrosis / drug therapy*
  • Cystic Fibrosis Transmembrane Conductance Regulator*
  • Humans

Substances

  • CFTR protein, human
  • Cystic Fibrosis Transmembrane Conductance Regulator